Amalgamated Bank Sells 8,752 Shares of Enovis Corporation (NYSE:ENOV)

Amalgamated Bank lessened its position in Enovis Corporation (NYSE:ENOV - Free Report) by 33.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,135 shares of the company's stock after selling 8,752 shares during the quarter. Amalgamated Bank's holdings in Enovis were worth $655,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its position in Enovis by 7.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 645,789 shares of the company's stock valued at $28,337,000 after buying an additional 44,970 shares during the period. Arizona State Retirement System grew its position in shares of Enovis by 2.6% during the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company's stock worth $711,000 after buying an additional 414 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Enovis during the fourth quarter valued at $16,407,000. PNC Financial Services Group Inc. raised its holdings in shares of Enovis by 4.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,737 shares of the company's stock valued at $471,000 after acquiring an additional 458 shares in the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of Enovis in the fourth quarter valued at about $275,000. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Price Performance

Shares of Enovis stock opened at $35.50 on Thursday. The firm has a market cap of $2.03 billion, a PE ratio of -2.54 and a beta of 1.70. Enovis Corporation has a twelve month low of $28.83 and a twelve month high of $49.83. The company has a quick ratio of 1.32, a current ratio of 2.55 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $32.97 and a 200 day moving average price of $37.80.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The business had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. During the same period in the prior year, the company posted $0.50 EPS. The business's quarterly revenue was up 8.2% on a year-over-year basis. Sell-side analysts predict that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ENOV has been the topic of a number of recent research reports. Needham & Company LLC dropped their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Evercore ISI cut their price objective on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research report on Tuesday. Canaccord Genuity Group cut their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, JMP Securities reduced their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Enovis presently has an average rating of "Moderate Buy" and an average price target of $55.60.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.